Jean-Jacques Bienaimé

Jean-Jacques Bienaimé

DirectoratBiomarin Pharmaceutical· In proxies 2021–2024

Pay in FY2023+20% from the year before · Biomarin Pharmaceutical stock -6.8% the same year

Jean-Jacques Bienaimé was paid $22.0M in FY2023 (Dec), up 20%. Biomarin Pharmaceutical stock fell 6.8% that year.

Pay$100 in the stock at the end of FY20 → $110
Pay is from the Summary Compensation Table of each Biomarin Pharmaceutical proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. ImmunomePublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  2. Biomarin PharmaceuticalPublic company · 5 yr
    • Director2021 – Present · 5 yrStock in role -37%
  3. Alpha-9 Oncology, Inc.Public company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  4. Keros Therapeutics, Inc.Public company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  5. Owkin, Inc.Public company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  6. Biotechnology Innovation OrganizationPublic company
    • Director? – PresentNo stock prices for these years
  7. Manufacturers of AmericaPublic company
    • Director? – PresentNo stock prices for these years
  8. Pharmaceutical ResearchPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?